Heron Therapeutics (HRTX) News
NASDAQ: HRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.2525-0.0116 (-4.39%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HRTX news summary
We found 6 recent headlines mentioning Heron Therapeutics (HRTX): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, HRTX is down 4.39% at $0.2525. The most recent story, "CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio", was published by Nasdaq on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Heron Therapeutics headlines
- CRMD to Acquire HRTX Assets for $223M Upfront to Expand PortfolioCorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.NasdaqCRMD, TGTX, HRTX, AMRX
- Heron Therapeutics Announces Third Quarter 2026 Financial ResultsCARY, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients…GlobeNewswire
- CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of CareAdds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platformGlobeNewswire
- Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026CARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host…GlobeNewswire
- CytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On Research(RTTNews) - CytoDyn Inc. (CYDY), a clinical-stage biotechnology company developing leronlimab for oncology indications, announced the appointment of Robert E. Hoffman as Chief Executive Officer…NasdaqANAB, HRTX, SUN
- Notable Wednesday Option Activity: HRTX, GLNG, KNSLAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Heron Therapeutics Inc (Symbol: HRTX), where a total of 41,920 contracts have traded so…NasdaqHRTX, GLNG, KNSL